Cargando…
Targeted therapies in development for non-small cell lung cancer
The iterative discovery in various malignancies during the past decades that a number of aberrant tumorigenic processes and signal transduction pathways are mediated by “druggable” protein kinases has led to a revolutionary change in drug development. In non-small cell lung cancer (NSCLC), the ErbB...
Autores principales: | Reungwetwattana, Thanyanan, Dy, Grace Kho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927069/ https://www.ncbi.nlm.nih.gov/pubmed/24574860 http://dx.doi.org/10.4103/1477-3163.123972 |
Ejemplares similares
-
Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
por: Korphaisarn, Krittiya, et al.
Publicado: (2021) -
CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
por: Majam, Teerapat, et al.
Publicado: (2023) -
Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma
por: Phruttinarakorn, Bantita, et al.
Publicado: (2020) -
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019) -
Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
por: Saifon, Woraseth, et al.
Publicado: (2022)